STAAR Surgical (NASDAQ:STAA) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

STAAR Surgical (NASDAQ:STAA) announced its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.06), FiscalAI reports. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. The firm had revenue of $93.53 million during the quarter, compared to analysts’ expectations of $90.60 million. During the same quarter in the previous year, the business posted ($0.34) EPS. The company’s revenue for the quarter was up 111.1% on a year-over-year basis.

Here are the key takeaways from STAAR Surgical’s conference call:

• Record first-half performance: Second-quarter revenue rose 111% year over year to $93.5 million, supported by sequential growth in China and double-digit growth across the Americas and EMEA excluding the Middle East.
• Profitability and cash flow improved materially. Net income reached $8.1 million versus a $16.8 million loss a year earlier, adjusted EBITDA was $20 million, and cash increased to $181.5 million with no debt; management expects to end 2026 with more than $200 million in cash.
• EVO+ is gaining traction in China and driving market-share gains. China revenue grew 10% sequentially to $52.3 million, EVO+ represented nearly one-third of units exiting the quarter, and the product commanded a premium without apparent customer resistance, although supply remains constrained.
• Near-term comparisons and operating headwinds remain significant. Third-quarter 2025 included a nonrecurring $25.9 million order, China is expected to be seasonally lower than the second quarter, and tariffs on U.S.-manufactured products will pressure margins until shipments to China are fully produced in Switzerland, targeted by the end of 2026.
• STAAR is broadening its innovation strategy beyond EVO. The company is preparing for first-in-human studies of next-generation products and plans to hire a chief technology officer to develop a broader, Collamer-centered ophthalmology platform.

STAAR Surgical Trading Up 1.9%

STAAR Surgical stock traded up $0.47 during mid-day trading on Wednesday, hitting $25.41. The company’s stock had a trading volume of 1,334,390 shares, compared to its average volume of 1,188,711. The stock’s fifty day moving average is $27.03 and its two-hundred day moving average is $24.04. The company has a current ratio of 5.12, a quick ratio of 4.31 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $1.27 billion, a PE ratio of -59.09 and a beta of 1.26. STAAR Surgical has a 1 year low of $15.59 and a 1 year high of $35.87.

Hedge Funds Weigh In On STAAR Surgical

A number of hedge funds have recently made changes to their positions in the stock. Invesco Ltd. raised its holdings in shares of STAAR Surgical by 0.6% in the third quarter. Invesco Ltd. now owns 150,896 shares of the medical instruments supplier’s stock worth $4,055,000 after acquiring an additional 956 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in STAAR Surgical by 2,605.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 1,016 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in STAAR Surgical by 2.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,535 shares of the medical instruments supplier’s stock valued at $1,214,000 after purchasing an additional 1,234 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of STAAR Surgical by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock worth $518,000 after purchasing an additional 1,267 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of STAAR Surgical by 3.7% during the fourth quarter. Deutsche Bank AG now owns 38,586 shares of the medical instruments supplier’s stock worth $891,000 after buying an additional 1,382 shares in the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

More STAAR Surgical News

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: Second-quarter revenue rose 111.1% year over year to approximately $93.5 million, exceeding analysts’ $90.6 million estimate. The company also improved from a loss in the prior-year period, reflecting strong demand for its implantable collamer lenses. STAAR Surgical: Q2 Earnings Snapshot
• Positive Sentiment: On an adjusted basis, STAAR Surgical reportedly earned $0.31 per share, above the Zacks consensus estimate of $0.21 and substantially better than the $0.07-per-share loss recorded a year earlier. STAAR Surgical Surpasses Q2 Earnings and Revenue Estimates
• Neutral Sentiment: Investor attention is turning to procedure demand and geographic sales mix, which could determine whether the company’s rapid growth is sustainable across key international markets. STAAR Surgical Procedure Demand and Geographic Mix Update
• Negative Sentiment: The company’s reported GAAP earnings were $0.16 per share, below the $0.22 consensus estimate. The discrepancy between the adjusted and GAAP figures likely contributed to the negative market reaction, particularly as STAAR Surgical still posted a negative net margin of 7.24%. STAAR Surgical Earnings Report

Analyst Ratings Changes

Several research firms recently commented on STAA. Canaccord Genuity Group increased their price target on STAAR Surgical from $27.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Wedbush restated an “outperform” rating and issued a $40.00 target price on shares of STAAR Surgical in a report on Tuesday, August 4th. Mizuho raised their target price on STAAR Surgical from $22.00 to $27.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Stifel Nicolaus lifted their price target on STAAR Surgical from $18.00 to $31.00 and gave the stock a “hold” rating in a report on Thursday, May 14th. Finally, Piper Sandler boosted their price target on shares of STAAR Surgical from $16.00 to $33.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $26.94.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.